Literature DB >> 27441758

Helix-Grafted Pleckstrin Homology Domains Suppress HIV-1 Infection of CD4-Positive Cells.

Rachel L Tennyson1, Susanne N Walker2, Terumasa Ikeda3, Reuben S Harris3,4, Alan J Kennan5, Brian R McNaughton6,7.   

Abstract

The size, functional group diversity and three-dimensional structure of proteins often allow these biomolecules to bind disease-relevant structures that challenge or evade small-molecule discovery. Additionally, folded proteins are often much more stable in biologically relevant environments compared to their peptide counterparts. We recently showed that helix-grafted display-extensive resurfacing and elongation of an existing solvent-exposed helix in a pleckstrin homology (PH) domain-led to a new protein that binds a surrogate of HIV-1 gp41, a validated target for inhibition of HIV-1 entry. Expanding on this work, we prepared a number of human-derived helix-grafted-display PH domains of varied helix length and measured properties relevant to therapeutic and basic research applications. In particular, we showed that some of these new reagents expressed well as recombinant proteins in Escherichia coli, were relatively stable in human serum, bound a mimic of pre-fusogenic HIV-1 gp41 in vitro and in complex biological environments, and significantly lowered the incidence of HIV-1 infection of CD4-positive cells.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD4-positive; HIV; peptides; pleckstrin homology

Mesh:

Substances:

Year:  2016        PMID: 27441758      PMCID: PMC6013031          DOI: 10.1002/cbic.201600329

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  25 in total

1.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 2.  HIV-1 gp41 as a target for viral entry inhibition.

Authors:  Michael J Root; H Kirby Steger
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

3.  Miniature protein inhibitors of the p53-hDM2 interaction.

Authors:  Joshua A Kritzer; Reena Zutshi; Mingtatt Cheah; F Ann Ran; Rachel Webman; Taritree M Wongjirad; Alanna Schepartz
Journal:  Chembiochem       Date:  2006-01       Impact factor: 3.164

4.  Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.

Authors:  W Seth Horne; Lisa M Johnson; Thomas J Ketas; Per Johan Klasse; Min Lu; John P Moore; Samuel H Gellman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

Review 5.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 6.  Peptide therapeutics: current status and future directions.

Authors:  Keld Fosgerau; Torsten Hoffmann
Journal:  Drug Discov Today       Date:  2014-10-17       Impact factor: 7.851

7.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 8.  Pleckstrin homology (PH) domains and phosphoinositides.

Authors:  Mark A Lemmon
Journal:  Biochem Soc Symp       Date:  2007

9.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

10.  A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Authors:  Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Edwin DeJesus; Roberto C Arduino; Joel E Gallant; Paul Volberding; Robert L Murphy; Fred Valentine; Emily L Nelson; Prakash R Sista; Alex Dusek; J Michael Kilby
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

View more
  1 in total

1.  Evaluation of sequence variability in HIV-1 gp41 C-peptide helix-grafted proteins.

Authors:  Rachel L Tennyson; Susanne N Walker; Terumasa Ikeda; Reuben S Harris; Brian R McNaughton
Journal:  Bioorg Med Chem       Date:  2017-08-01       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.